NCT05579574View on ClinicalTrials.gov

A Study to Investigate the Interaction of BMS-986322 and a Combined Oral Hormonal Contraceptive (Ethinyl Estradiol [EE]/Norethindrone [NET]) in Healthy Female Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

October 21, 2022

Primary Completion Date

June 1, 2023

Study Completion Date

June 1, 2023

Conditions
Healthy Participants
Interventions
DRUG

BMS-986322

Specified dose on specified days

DRUG

Loestrin

Specified dose on specified days

Trial Locations (2)

92801

Local Institution - 0001, Anaheim

Local Institution - 0002, Anaheim

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05579574 - A Study to Investigate the Interaction of BMS-986322 and a Combined Oral Hormonal Contraceptive (Ethinyl Estradiol [EE]/Norethindrone [NET]) in Healthy Female Participants | Biotech Hunter | Biotech Hunter